Serological distinction between DR antigens and lymphocyte activating determinants

Area of Science:

• Immunology
• Cell Biology

Background:

• The EB1 B cell line, derived from Burkitt lymphoma, exhibits low stimulatory capacity in mixed lymphocyte culture (MLC).
• Understanding the molecular basis of lymphocyte activation and recognition is critical in immunology.

Purpose of the Study:

• To characterize the stimulatory molecules involved in mixed lymphocyte culture (MLC).
• To identify and differentiate novel antigens from the known HLA-DR antigens involved in lymphocyte activation.

Main Methods:

• Generation of a rabbit antiserum against the DAUDI B cell line.
• Absorption of the antiserum with the EB1 cell line.
• Assays for mixed lymphocyte culture (MLC) stimulation and lectin-induced proliferation.
• Indirect immunofluorescence and 125I-staphylococcal protein A binding assays to detect antigen expression.

Main Results:

• The absorbed antiserum inhibited MLC stimulation by both B cell lines and allogeneic lymphocytes.
• Lectin-induced proliferation remained unaffected, indicating specificity for MLC-related activation.
• The target antigen was detected on peripheral B and T cells, as well as B lymphoblastoid and myeloma lines.
• The identified antigen was distinct from the serologically defined DR antigens.

Conclusions:

• The antiserum is likely directed against lymphocyte activating determinants (LADs).
• LADs play a significant role in allogeneic lymphocyte recognition and activation during MLC.
• These LADs are distinct from HLA-DR antigens, suggesting a separate pathway in immune cell interactions.